Shares of TransMedics Group Inc. (TMDX) are up over 20% at $96 in premarket trading Tuesday, thanks to stellar financial results for the quarter and year ended December 31, 2023.
This medical technology company has developed technologies to preserve organ quality and assess organ viability prior to transplant for patients with end-stage lung, heart, and liver failure.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com